Search
Fuyuan Pharmaceutical Hits 2 Daily Limits: Innovative Class 1 Drug FY101 Injection Continues Phase I Clinical Trial
2025-08-04 /
Read about 0 minute
Author：小编
Fuyuan Pharmaceutical has announced that the market's interest in its innovative drug business has surged recently. The company's proprietary Class 1 drug, FY101 Injection, has secured approval for clinical trials and is presently undergoing Phase I trials for the treatment of hyperlipidemia. Nevertheless, the outcome of these trials remains highly uncertain.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
